The second partial responder was a 67-year-old woman with stage IV ER+ PR+ HER2− primary breast cancer with metastasis to lymph node, bone, lung, and liver with two prior lines of treatment (fulvestrant and letrozole/palbociclib) for metastatic disease. Here, ERBB2 is linked to metastatic neoplasm.